Advanced search
Publication Cover
Acta Oncologica Volume 50, 2011 - Issue 5
Journal homepage
1,444
Views
33
CrossRef citations to date
0
Altmetric
Research Article

Insulin glargine use and short-term incidence of malignancies — a three-year population-based observation

Rickard Ljung Swedish National Board of Health and Welfare, Stockholm, Sweden; Upper Gastrointestinal Research, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Equity and Health Policy, Department of Public Health Sciences, Karolinska Institutet, Stockholm, SwedenCorrespondence[email protected]
,
Mats Talbäck Swedish National Board of Health and Welfare, Stockholm, Sweden
,
Bengt Haglund Swedish National Board of Health and Welfare, Stockholm, Sweden
,
Junmei Miao Jonasson Division of Clinical Cancer Epidemiology, Department of Oncology, The Sahlgrenska Academy, Onkologiskt Centrum, Gothenburg, Sweden; Division of Clinical Cancer Epidemiology, Department of Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden; National Diabetes Register, Register Center, Västra Götaland Region, Sweden
,
Soffia Gudbjörnsdòttir Diabetes Centre, Sahlgrenska University Hospital, Gothenburg, Sweden; Nordic School of Public Health, Gothenburg, Sweden; National Diabetes Register, Register Center, Västra Götaland Region, Sweden
&
Gunnar Steineck Division of Clinical Cancer Epidemiology, Department of Oncology, The Sahlgrenska Academy, Onkologiskt Centrum, Gothenburg, Sweden
Pages 685-693 | Received 04 Nov 2010, Accepted 21 Jan 2011, Published online: 21 Apr 2011

Citations (33)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Marco Tuccori, Irma Convertino, Maria Teresa Galiulo, Alessandra Marino, Alice Capogrosso-Sansone & Corrado Blandizzi. (2017) Diabetes drugs and the incidence of solid cancers: a survey of the current evidence. Expert Opinion on Drug Safety 16:10, pages 1133-1148.
Read now
Marc Rendell, Halis Kaan Akturk & Sri Harsha Tella. (2013) Glargine safety, diabetes and cancer. Expert Opinion on Drug Safety 12:2, pages 247-263.
Read now
Norbert Tennagels & Ulrich Werner. (2013) The metabolic and mitogenic properties of basal insulin analogues. Archives of Physiology and Biochemistry 119:1, pages 1-14.
Read now
Rickard Ljung, Mats Talbäck, Bengt Haglund, Junmei Miao Jonasson, Soffia Gudbjörnsdòttir & Gunnar Steineck. (2012) Insulin glargine use and short-term incidence of breast cancer — a four-year population-based observation. Acta Oncologica 51:3, pages 400-402.
Read now

Articles from other publishers (29)

Jiying Qi, Ping He, Huayan Yao, Wen Sun, Ping Lu, Zizheng Zhang, Bin Cui & Guang Ning. (2023) Insulin glargine use and cancer risk among patients with type 2 diabetes mellitus: a real-world study in Shanghai, China. International Journal of Diabetes in Developing Countries.
Crossref
Cathrine Axfors, Chirag J. Patel & John P.A. Ioannidis. (2023) Published registry-based pharmacoepidemiologic associations show limited concordance with agnostic medication-wide analyses. Journal of Clinical Epidemiology 160, pages 33-45.
Crossref
Richeek Pradhan, Hui Yin, Oriana H. Y. Yu & Laurent Azoulay. (2019) The Use of Long-Acting Insulin Analogs and the Risk of Colorectal Cancer Among Patients with Type 2 Diabetes: A Population-Based Cohort Study. Drug Safety 43:2, pages 103-110.
Crossref
Morten Hasselstrøm Jensen, Ole Hejlesen & Peter Vestergaard. (2019) Risk of major cardiovascular events, severe hypoglycaemia, and all‐cause mortality for users of insulin degludec versus insulin glargine U100—A Danish cohort study. Diabetes/Metabolism Research and Reviews 36:1.
Crossref
Yusaku Mori, Eunhyoung Ko, Rudolf Furrer, Linda C Qu, Stuart C Wiber, I George Fantus, Mario Thevis, Alan Medline & Adria Giacca. (2018) Effects of insulin and analogues on carcinogen-induced mammary tumours in high-fat-fed rats. Endocrine Connections 7:5, pages 739-748.
Crossref
Jennifer W. WuLaurent AzoulayAgnieszka MajdanJean-François BoivinMichael PollakSamy Suissa. (2017) Long-Term Use of Long-Acting Insulin Analogs and Breast Cancer Incidence in Women With Type 2 Diabetes. Journal of Clinical Oncology 35:32, pages 3647-3653.
Crossref
Lan Mu, Nannan Zhu, Jiao Zhang, Fang Xing, Daiqing Li & Xin Wang. (2017) Type 2 diabetes, insulin treatment and prognosis of breast cancer. Diabetes/Metabolism Research and Reviews 33:1, pages e2823.
Crossref
Jennifer W. Wu, Kristian B. Filion, Laurent Azoulay, Margaret K. Doll & Samy Suissa. (2016) Effect of Long-Acting Insulin Analogs on the Risk of Cancer: A Systematic Review of Observational Studies. Diabetes Care 39:3, pages 486-494.
Crossref
Heleen K Bronsveld, Bas ter Braak, Øystein Karlstad, Peter Vestergaard, Jakob Starup-Linde, Marloes T Bazelier, Marie L De Bruin, Anthonius de Boer, Christine L E Siezen, Bob van de Water, Jan Willem van der Laan & Marjanka K Schmidt. (2015) Treatment with insulin (analogues) and breast cancer risk in diabetics; a systematic review and meta-analysis of in vitro, animal and human evidence. Breast Cancer Research 17:1.
Crossref
Bas ter Braak, Steven Wink, Esmee Koedoot, Chantal Pont, Christine Siezen, Jan Willem van der Laan & Bob van de Water. (2015) Alternative signaling network activation through different insulin receptor family members caused by pro-mitogenic antidiabetic insulin analogues in human mammary epithelial cells. Breast Cancer Research 17:1.
Crossref
Bas ter Braak, Christine Siezen, Ewoud N Speksnijder, Esmee Koedoot, Harry van Steeg, Daniela CF Salvatori, Bob van de Water & Jan Willem van der Laan. (2015) Mammary gland tumor promotion by chronic administration of IGF1 and the insulin analogue AspB10 in the p53R270H/+WAPCre mouse model. Breast Cancer Research 17:1.
Crossref
ATSUSHI IMAI, SATOSHI ICHIGO, KAZUTOSHI MATSUNAMI, HIROSHI TAKAGI & KEIGO YASUDA. (2015) Clinical benefits of metformin in gynecologic oncology. Oncology Letters 10:2, pages 577-582.
Crossref
Lamiae Grimaldi-Bensouda, David CameronMichel Marty, Anthony H. BarnettFrédérique Penault-Llorca, Michael Pollak, Bernard Charbonnel, Matthew Riddle, Laurent Mignot, Jean-François Boivin, Artak KhachatryanMichel Rossignol, Jacques Bénichou, Annick Alpérovitch & Lucien Abenhaim. (2014) Risk of Breast Cancer by Individual Insulin Use: An International Multicenter Study. Diabetes Care 37:1, pages 134-143.
Crossref
Laurel A. Habel, Kim N. Danforth, Charles P. Quesenberry, Angela Capra, Stephen K. Van Den Eeden, Noel S. Weiss & Assiamira Ferrara. (2013) Cohort Study of Insulin Glargine and Risk of Breast, Prostate, and Colorectal Cancer Among Patients With Diabetes. Diabetes Care 36:12, pages 3953-3960.
Crossref
Nikola Besic & Nika Satej. (2013) Insulin glargine versus other types of basal insulin–clinical and tumor characteristics in patients with breast carcinoma. BMC Research Notes 6:1.
Crossref
Siddharth Singh, Harkirat Singh, Preet Paul Singh, M. Hassan Murad & Paul J. Limburg. (2013) Antidiabetic Medications and the Risk of Colorectal Cancer in Patients with Diabetes Mellitus: A Systematic Review and Meta-analysis. Cancer Epidemiology, Biomarkers & Prevention 22:12, pages 2258-2268.
Crossref
Yan-bo Chen, Qi Chen, Zhong Wang & Juan Zhou. (2013) Insulin Therapy and Risk of Prostate Cancer: a Systematic Review and Meta-Analysis of Observational Studies. PLoS ONE 8:11, pages e81594.
Crossref
Til Stürmer, M. Alison Marquis, Haibo Zhou, James B. Meigs, Soo Lim, Lawrence Blonde, Eileen MacDonald, Ray Wang, Lisa M. LaVange, Virginia Pate & John B. Buse. (2013) Cancer Incidence Among Those Initiating Insulin Therapy With Glargine Versus Human NPH Insulin. Diabetes Care 36:11, pages 3517-3525.
Crossref
Jean-Paul Fagot, Pierre-Olivier Blotière, Philippe Ricordeau, Alain Weill, François Alla & Hubert Allemand. (2013) Does Insulin Glargine Increase the Risk of Cancer Compared With Other Basal Insulins?. Diabetes Care 36:2, pages 294-301.
Crossref
Xulei Tang, Lin Yang, Zhiyu He & Jingfang Liu. (2012) Insulin Glargine and Cancer Risk in Patients with Diabetes: A Meta-Analysis. PLoS ONE 7:12, pages e51814.
Crossref
I.N. Colmers, S.L. Bowker, L.A. Tjosvold & J.A. Johnson. (2012) Insulin use and cancer risk in patients with type 2 diabetes: A systematic review and meta-analysis of observational studies. Diabetes & Metabolism 38:6, pages 485-506.
Crossref
Edoardo Mannucci. (2012) Insulin Therapy and Cancer in Type 2 Diabetes. ISRN Endocrinology 2012, pages 1-12.
Crossref
Pamela J. Goodwin, Alastair M. Thompson & Vuk Stambolic. (2012) Diabetes, Metformin, and Breast Cancer: Lilac Time?. Journal of Clinical Oncology 30:23, pages 2812-2814.
Crossref
Xinli Du, Rihua Zhang, Yi Xue, Dong Li, Jinmei Cai, Suming Zhou, Zhengkai Huang, Rongbin Yu & Yun Liu. (2018) Insulin Glargine and Risk of Cancer: A Meta-Analysis. The International Journal of Biological Markers 27:3, pages 241-246.
Crossref
Adedayo A. Onitilo, Jessica M. Engel, Ingrid Glurich, Rachel V. Stankowski, Gail M. Williams & Suhail A. Doi. (2012) Diabetes and cancer II: role of diabetes medications and influence of shared risk factors. Cancer Causes & Control 23:7, pages 991-1008.
Crossref
Junmei Miao Jonasson, Jan Cederholm, Bj?rn Eliasson, Bj?rn Zethelius, Katarina Eeg-Olofsson & Soffia Gudbj?rnsdottir. (2012) HbA1C and Cancer Risk in Patients with Type 2 Diabetes ? A Nationwide Population-Based Prospective Cohort Study in Sweden. PLoS ONE 7:6, pages e38784.
Crossref
Jaakko Tuomilehto. (2012) Should we consider cancer diagnosis in diabetic patients as a complication of diabetes, or is it iatrogenic sequelae?. Primary Care Diabetes 6:1, pages 1-2.
Crossref
Marcus Lind, Martin Fahl?n, Bj?rn Eliasson & Anders Od?n. (2012) The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: An observational study of the time-dependent effects of antidiabetic treatments in patients with diabetes. Primary Care Diabetes 6:1, pages 53-59.
Crossref
P. Blin, R. Lassalle, C. Dureau-Pournin, B. Ambrosino, M. A. Bernard, A. Abouelfath, H. Gin, C. Le Jeunne, A. Pariente, C. Droz & N. Moore. (2012) Insulin glargine and risk of cancer: a cohort study in the French National Healthcare Insurance Database. Diabetologia 55:3, pages 644-653.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.